The Global Initiative to Speed the Delivery of Therapies for FSHD

Globe

These questions led to the formation of Project Mercury, a patient-led collaborative global initiative to ensure timely access to effective and affordable treatments for people affected by facioscapulohumeral muscular dystrophy (FSHD) everywhere.

About Project Mercury

About Project Mercury

Learn More
See how others are celebrating World FSHD Day

News & Updates

Project Mercury at the 295th ENMC Workshop: Advancing Harmonized, Patient‑Centered Clinical Monitoring in FSHD

From 1–3 May 2026, representatives from Project Mercury participated in the 295th ENMC International Workshop on “Harmonizing Clinical Monitoring in FSHD”, held in Hoofddorp, The Netherlands. The workshop brought together leading clinicians, physical therapists, outcomes researchers, industry representatives, and patient organizations with a shared objective: to move toward global consensus

Read More »

Project Mercury: From Alignment to Action – Global Task Force Advances Readiness, Access, and Sustainability

In April, the Project Mercury Global Task Force (GTF) convened virtually for its quarterly meeting, bringing together patient advocacy leaders, clinicians, researchers, and partners from across regions. Building on the momentum described in our previous update, this meeting focused on turning alignment into execution as the initiative enters its final

Read More »

Project Mercury at SOLVE FSHD

Early April, Project Mercury was proud to be represented at the SOLVE FSHD meeting in Canada, where our Chair, Emma Weatherley, shared our work with an international community of researchers, clinicians, industry partners, and patient advocates. The meeting provided a valuable opportunity to connect with leaders from across the FSHD

Read More »

This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101132943. The JU receives support from the European Union’s Horizon Europe research and innovation programme, COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe (and the FSHD Society and TREAT-NMD Services Ltd as contributing beneficiaries participating in the project). The project will also receive funding from UK Research and Innovation (UKRI) under the UK government’s Horizon Europe funding guarantee [grant numbers 10105921, 10103989, and 10083579].

Funded by the European Union, the private members, and those contributing beneficiaries of the IHI JU. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.

Translate »